b
r
c
vero
cell
base
vaccin
candid
chandipura
chp
viru
rhabdovirida
vesiculoviru
develop
evalu
immunogen
mice
viru
purifi
ultracentrifug
glycerol
cushion
follow
differenti
centrifug
sucros
gradient
inactiv
lacton
concentr
inactiv
product
blend
aluminium
phosphat
immun
swiss
albino
mice
neutral
antibodi
rang
detect
seroconvers
dose
respect
immun
mice
antibodi
titer
surviv
live
viru
challeng
vaccin
candid
potenti
effici
vaccin
chp
viru
chandipura
viru
chpv
member
famili
rhabdovirida
genu
vesiculoviru
implic
etiolog
agent
encephalitislik
highli
fatal
outbreak
sever
district
andhra
pradesh
ap
maharashtra
chpv
novel
viru
caus
febril
ill
man
discov
accident
outbreak
investig
denguechikungunyalik
ill
nagpur
district
maharashtra
india
viru
isol
subsequ
occas
phlebotomu
sand
fli
human
howev
due
low
pathogen
human
much
attent
given
viru
resurg
virul
form
kill
children
ap
case
fatal
rate
cfr
death
occur
within
h
onset
symptom
outbreak
compar
sever
gujarat
children
die
admit
cfr
death
occur
within
h
sporad
case
report
everi
year
endem
area
ap
maharashtra
patient
treat
symptomat
effect
vaccin
therapeut
avail
develop
evalu
subunit
vaccin
report
recent
produc
good
immunogen
laboratori
anim
attempt
therefor
made
develop
tissu
cultur
base
inactiv
vaccin
candid
viru
correspond
author
tel
fax
email
address
rediffmailcom
ac
mishra
viru
stock
prepar
vero
cell
line
use
plaqu
purifi
strain
chpv
strain
cell
line
viru
em
screen
consecut
passag
rule
contamin
cell
grown
cm
tissu
cultur
flask
nunc
denmark
dmem
supplement
fb
invitrogen
usa
viru
infect
harvest
viru
quantit
storag
carri
describ
earlier
brief
cell
form
confluent
monolay
infect
moi
viru
incub
h
c
intermitt
rock
everi
min
incub
inoculum
discard
cell
wash
twice
pb
fed
mainten
medium
dmem
contain
fb
cell
incub
c
observ
invert
microscop
appear
cytopath
effect
cpe
harvest
cell
exhibit
cpe
cultur
freezethaw
thrice
centrifug
cell
lysat
rpm
refriger
centrifug
min
collect
supernat
transfer
onto
tube
contain
ml
glycerol
nte
buffer
ultra
centrifug
rpm
h
c
viru
pellet
suspend
l
nte
buffer
pool
load
sucros
gradient
centrifug
rpm
h
transluc
zone
sucros
sucros
collect
care
contain
maximum
virion
ultra
centrifug
rpm
h
pellet
collect
suspend
nte
buffer
store
c
use
amount
protein
purifi
live
viru
inactiv
viru
estim
use
lowri
method
known
amount
protein
separ
resolv
stack
sdspage
mini
electrophoresi
unit
biorad
usa
v
h
protein
transfer
v
min
onto
nitrocellulos
membran
wet
condit
use
transblot
apparatu
biorad
usa
unoccupi
bind
site
block
wv
bovin
serum
albumin
bsa
pb
ph
h
room
temperatur
prior
immunoassay
membran
wash
thrice
min
wash
buffer
compris
wv
bsa
pb
vv
tween
sigma
usa
incub
primari
antibodi
hyper
immun
serum
rais
mice
chpv
dilut
h
c
membran
wash
wash
buffer
incub
antimic
ap
conjug
sigma
usa
dilut
membran
wash
twice
pbst
develop
bcipnbt
premix
substrat
solut
till
band
appear
wash
membran
distil
water
termin
reaction
bpl
sigma
st
loui
mo
usa
mix
viru
stock
get
concentr
stir
continu
magnet
stirrer
c
aliquot
l
collect
everi
min
bpl
activ
neutral
ad
l
sodium
thiosulph
store
c
complet
experi
sampl
collect
min
sequenti
sampl
titrat
rd
cell
inactiv
kinet
determin
fig
sampl
induc
cpe
cell
line
determin
complet
inactiv
product
time
point
taken
time
complet
inactiv
mice
immun
studi
chpv
treat
bpl
doubl
time
requir
complet
inactiv
stock
solut
mgml
alpo
sigma
chemic
co
usa
dilut
inactiv
chpv
suspens
get
final
concentr
mgml
mix
thoroughli
magnet
stirrer
h
c
test
maximum
bind
sampl
centrifug
rpm
min
c
pellet
supernat
collect
viru
titer
determin
describ
earlier
immun
inactiv
viru
precipit
alpo
mgml
gave
maximum
bind
posit
control
neg
control
also
test
simultan
former
constitut
purifi
chpv
alpo
neg
control
constitut
normal
vero
tissu
cultur
fluid
mix
concentr
alpo
threeto
swiss
albino
mice
prebl
test
nantibodi
chpv
mice
immun
done
subcutan
abdomin
area
test
mice
immun
alpo
adsorb
inactiv
chpv
mlmice
posit
control
mice
immun
purifi
live
viru
adsorb
alpo
neg
control
mice
inocul
normal
tcf
adsorb
alpo
concentr
test
sampl
bleed
done
day
dose
retroorbit
rout
light
anesthesia
sera
separ
screen
chpv
antibodi
neutral
test
nt
immun
mice
challeng
day
third
dose
l
live
viru
pfu
intra
cranial
ic
rout
observ
day
addit
set
posit
neg
control
also
use
challeng
experi
verifi
techniqu
viru
infect
normal
unimmun
mice
age
use
studi
posit
control
receiv
live
viru
neg
control
receiv
dmem
mice
kept
ideal
condit
observ
sick
death
determin
potenc
vaccin
candid
mice
immun
differ
dilut
vaccin
mice
bled
antibodi
titer
determin
immun
mice
also
challeng
live
viru
observ
posit
neg
control
also
use
studi
log
gmt
valu
differ
dose
compar
pair
test
use
spss
softwar
surviv
analysi
carri
pasw
statist
replica
experi
combin
togeth
order
increas
sampl
size
mice
experi
kaplanmei
plot
use
show
surviv
respect
time
sinc
mice
follow
day
mice
remain
day
treat
censor
surviv
three
differ
test
log
rank
test
breslow
test
taronewar
test
use
compar
mean
surviv
time
differ
group
though
chpv
replic
sever
system
vero
cell
line
use
larg
scale
propag
due
eas
downstream
process
chicken
embryo
though
produc
highest
titer
viru
found
difficult
purifi
among
variou
method
employ
purifi
chpv
vero
tissu
cultur
fluid
tcf
ultra
centrifug
glycerol
cushion
follow
discontinu
sucros
gradient
gave
maximum
viru
yield
lowest
level
contamin
protein
protein
profil
purifi
product
analyz
sdspage
western
blot
sdspage
profil
clearli
demonstr
presenc
specif
chpv
protein
band
western
blot
analysi
clearli
demonstr
g
n
p
protein
equival
molecular
weight
rang
kda
observ
chpv
prior
inactiv
fig
complet
inactiv
chpv
titer
log
tcid
ml
bpl
concentr
achiev
min
c
inactiv
gradual
steadi
drop
titer
approxim
log
per
min
fig
complet
inactiv
chpv
demonstr
vitro
ovo
vivo
three
consecut
passag
nt
studi
tissu
cultur
demonstr
product
antibodi
dose
depend
antibodi
titer
nt
increas
everi
dose
reach
maximum
dose
fig
compar
increas
antibodi
titer
also
observ
differ
dilut
vaccin
use
immun
though
low
level
two
dose
nt
titer
rang
howev
third
dose
nt
antibodi
titer
increas
rang
antibodi
titer
obtain
immun
live
viru
given
fig
sero
convers
rate
second
third
dose
respect
mice
nt
titer
surviv
challeng
test
three
test
show
mean
surviv
time
viru
significantli
vaccin
vaccin
vaccin
p
comparison
mean
surviv
time
vaccin
group
differ
significantli
p
pair
fig
chpv
emerg
import
pediatr
encephalitiscaus
pathogen
high
case
fatal
rate
central
india
diseas
predominantli
rural
major
patient
belong
low
socioeconom
class
societi
viru
transmit
sand
fli
breed
crack
crevic
around
human
habitat
high
case
fatal
rate
rapid
progress
diseas
warrant
need
effect
vaccin
immun
children
endem
area
recombin
candid
vaccin
use
chpv
gprotein
report
develop
recent
protect
mice
gene
ggene
express
baculoviru
express
system
hplc
purifi
use
mice
immun
three
dose
given
interv
week
concentr
one
microgram
antichpv
igg
antibodi
observ
earli
week
immun
live
viru
challeng
ic
rout
demonstr
protect
also
observ
neutral
homolog
heterolog
virus
antisera
investig
also
demonstr
induct
arm
immun
respons
vaccin
evalu
combin
commerci
avail
dpt
vaccin
determin
efficaci
combin
view
cover
local
endem
popul
combin
yield
ident
result
observ
chpv
vaccin
howev
clinic
trial
report
vaccin
therefor
made
attempt
develop
vero
cell
base
bpl
inactiv
vaccin
chpv
vero
cell
line
select
propag
viru
due
eas
manag
scale
downstream
process
also
approv
regulatori
author
vaccin
develop
sever
human
pathogen
studi
sever
techniqu
use
standard
chpv
purif
without
signific
loss
biolog
activ
use
cellophan
sulphat
millipor
india
ltd
bioscienc
divis
purif
yield
chpv
biolog
activ
though
use
success
purifi
rabi
viru
claim
manufactur
gel
filtrat
chromatographi
use
sephacryl
sigma
chemic
co
usa
also
use
per
manufactur
instruct
purifi
viru
howev
yield
purifi
chpv
biolog
activ
low
chpv
purif
use
column
chromatographi
also
success
due
low
yield
viru
biolog
activ
use
ultracentrifug
glycerol
cushion
follow
centrifug
discontinu
sucros
gradient
found
effect
achiev
highest
amount
purifi
viru
demonstr
sdspage
western
blot
fig
bpl
emerg
import
inactiv
agent
extens
use
vaccin
product
retain
antigen
immunogen
viral
protein
addit
sever
bpl
inactiv
candid
vaccin
poliomyel
sever
acut
respiratori
syndrom
human
immunodefici
viru
current
evalu
anim
model
human
clinic
trial
bpl
sever
advantag
chemic
complet
hydrolys
incub
c
isom
lactat
acid
nontox
degrad
product
found
normal
human
bodi
byproduct
fat
metabol
addit
viru
inactiv
bpl
also
serv
intern
bactericid
fungicid
react
nucleic
acid
microbi
contamin
degrad
organ
adjuv
alum
aluminium
phosphat
concentr
mgml
use
present
studi
demonstr
enhanc
immunogen
viral
vaccin
adjuv
use
improv
immunogen
weak
antigen
especi
enhanc
speed
durat
immun
respons
well
increas
effici
vaccin
toxoid
increas
avail
antigen
lymphat
system
complet
bind
chpv
demonstr
present
studi
immunogen
potenti
bpl
inactiv
chpv
vaccin
assess
determin
neutral
antibodi
gener
three
success
dose
vaccin
neutral
also
use
marker
determin
protect
efficaci
studi
therefor
demonstr
efficaci
vaccin
protect
immun
mice
howev
vaccin
evalu
nonhuman
primat
consid
use
human
studi
demonstr
develop
effici
vaccin
candid
chpv
even
two
dose
vaccin
found
effici
give
protect
immun
mice
antibodi
titer
third
dose
rang
mice
demonstr
neutral
antibodi
titer
surviv
live
viru
challeng
intra
cranial
rout
studi
also
demonstr
bpl
effici
inactiv
agent
inactiv
chpv
retain
immunogen
antigen
properti
viru
